CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel
Panelists discuss how patient selection criteria and individual characteristics help determine whether ide-cel or cilta-cel is the more appropriate chimeric antigen receptor T-cell therapy choice for early-line treatment in patients with multiple myeloma.
Video content above is prompted by the following:
- Which patients do you think about for chimeric antigen receptor T-cell therapy (CAR T) in second-line treatment for relapsed/refractory multiple myeloma (cilta-cel vs ide-cel)?
- Dr Usmani to ask Dr Mailankody: Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T referral?
- How do nonmedical factors (location, money, etc) impact patient selection?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
